594 related articles for article (PubMed ID: 25643273)
1. Acinetobacter baumannii: evolution of antimicrobial resistance-treatment options.
Doi Y; Murray GL; Peleg AY
Semin Respir Crit Care Med; 2015 Feb; 36(1):85-98. PubMed ID: 25643273
[TBL] [Abstract][Full Text] [Related]
2. In vitro synergistic activity of colistin with tigecycline or β-lactam antibiotic/β-lactamase inhibitor combinations against carbapenem-resistant Acinetobacter baumannii.
Karaoglan I; Zer Y; Bosnak VK; Mete AO; Namiduru M
J Int Med Res; 2013 Dec; 41(6):1830-7. PubMed ID: 24265334
[TBL] [Abstract][Full Text] [Related]
3. Global spread of drug-resistant Acinetobacter baumannii: molecular epidemiology and management of antimicrobial resistance.
Durante-Mangoni E; Zarrilli R
Future Microbiol; 2011 Apr; 6(4):407-22. PubMed ID: 21526942
[TBL] [Abstract][Full Text] [Related]
4. Emergence of resistance to carbapenems in Acinetobacter baumannii in Europe: clinical impact and therapeutic options.
Kempf M; Rolain JM
Int J Antimicrob Agents; 2012 Feb; 39(2):105-14. PubMed ID: 22113193
[TBL] [Abstract][Full Text] [Related]
5. [Epidemiology and clinical features of Acinetobacter baumannii infections in humans].
Wisplinghoff H; Seifert H
Berl Munch Tierarztl Wochenschr; 2014; 127(11-12):447-57. PubMed ID: 25872254
[TBL] [Abstract][Full Text] [Related]
6. Spread of a carbapenem- and colistin-resistant Acinetobacter baumannii ST2 clonal strain causing outbreaks in two Sicilian hospitals.
Agodi A; Voulgari E; Barchitta M; Quattrocchi A; Bellocchi P; Poulou A; Santangelo C; Castiglione G; Giaquinta L; Romeo MA; Vrioni G; Tsakris A
J Hosp Infect; 2014 Apr; 86(4):260-6. PubMed ID: 24680473
[TBL] [Abstract][Full Text] [Related]
7. Therapeutic options for Acinetobacter baumannii infections.
Vila J; Pachón J
Expert Opin Pharmacother; 2008 Mar; 9(4):587-99. PubMed ID: 18312160
[TBL] [Abstract][Full Text] [Related]
8. Multidrug-resistant Acinetobacter baumannii: mechanisms of virulence and resistance.
Gordon NC; Wareham DW
Int J Antimicrob Agents; 2010 Mar; 35(3):219-26. PubMed ID: 20047818
[TBL] [Abstract][Full Text] [Related]
9. Colistin resistance of Acinetobacter baumannii: clinical reports, mechanisms and antimicrobial strategies.
Cai Y; Chai D; Wang R; Liang B; Bai N
J Antimicrob Chemother; 2012 Jul; 67(7):1607-15. PubMed ID: 22441575
[TBL] [Abstract][Full Text] [Related]
10. Treatment of Acinetobacter infections.
Michalopoulos A; Falagas ME
Expert Opin Pharmacother; 2010 Apr; 11(5):779-88. PubMed ID: 20210684
[TBL] [Abstract][Full Text] [Related]
11. [Antibiotic resistance of Acinetobacter baumannii strains isolated from clinical specimens in the "Marius Nasta" Pneumology Institute, Bucharest].
Moisoiu A; Ionită M; Sârbu L; Stoica C; Grigoriu L
Pneumologia; 2014; 63(2):109-11. PubMed ID: 25241558
[TBL] [Abstract][Full Text] [Related]
12. Cationic amphiphilic alpha-helical peptides for the treatment of carbapenem-resistant Acinetobacter baumannii infection.
Huang Y; Wiradharma N; Xu K; Ji Z; Bi S; Li L; Yang YY; Fan W
Biomaterials; 2012 Dec; 33(34):8841-7. PubMed ID: 22925814
[TBL] [Abstract][Full Text] [Related]
13. Role of tigecycline in the control of a carbapenem-resistant Acinetobacter baumannii outbreak in an intensive care unit.
Jamal W; Salama M; Dehrab N; Al Hashem G; Shahin M; Rotimi VO
J Hosp Infect; 2009 Jul; 72(3):234-42. PubMed ID: 19493588
[TBL] [Abstract][Full Text] [Related]
14. Efficacy of monotherapy and combined antibiotic therapy for carbapenem-resistant Acinetobacter baumannii pneumonia in an immunosuppressed mouse model.
Song JY; Cheong HJ; Lee J; Sung AK; Kim WJ
Int J Antimicrob Agents; 2009 Jan; 33(1):33-9. PubMed ID: 18835761
[TBL] [Abstract][Full Text] [Related]
15. Biology of
Lee CR; Lee JH; Park M; Park KS; Bae IK; Kim YB; Cha CJ; Jeong BC; Lee SH
Front Cell Infect Microbiol; 2017; 7():55. PubMed ID: 28348979
[No Abstract] [Full Text] [Related]
16. Efficacy of tigecycline/colistin combination in a pneumonia model caused by extensively drug-resistant Acinetobacter baumannii.
Mutlu Yilmaz E; Sunbul M; Aksoy A; Yilmaz H; Guney AK; Guvenc T
Int J Antimicrob Agents; 2012 Oct; 40(4):332-6. PubMed ID: 22831842
[TBL] [Abstract][Full Text] [Related]
17. Acinetobacter baumannii: an emerging multidrug-resistant threat.
Gootz TD; Marra A
Expert Rev Anti Infect Ther; 2008 Jun; 6(3):309-25. PubMed ID: 18588496
[TBL] [Abstract][Full Text] [Related]
18. Emergence of colistin resistance without loss of fitness and virulence after prolonged colistin administration in a patient with extensively drug-resistant Acinetobacter baumannii.
Durante-Mangoni E; Del Franco M; Andini R; Bernardo M; Giannouli M; Zarrilli R
Diagn Microbiol Infect Dis; 2015 Jul; 82(3):222-6. PubMed ID: 25858028
[TBL] [Abstract][Full Text] [Related]
19. Drug treatment for multidrug-resistant Acinetobacter baumannii infections.
Bassetti M; Righi E; Esposito S; Petrosillo N; Nicolini L
Future Microbiol; 2008 Dec; 3(6):649-60. PubMed ID: 19072182
[TBL] [Abstract][Full Text] [Related]
20. Acinetobacter baumannii: a universal threat to public health?
Giamarellou H; Antoniadou A; Kanellakopoulou K
Int J Antimicrob Agents; 2008 Aug; 32(2):106-19. PubMed ID: 18571905
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
